The deployment of general-purpose large language models (LLMs) in the pharmaceutical industry is constrained by three fundamental challenges: the inability of generic models to reason reliably over organization-specific content; the data privacy requirements imposed by regulatory frameworks such as FDA 21 CFR Part 11, HIPAA, and GDPR, which prohibit transmission of proprietary data to external cloud-based AI services; and the risk of system misuse through unauthorized access or adversarial exploitation. To overcome these challenges, this paper proposes a modular, privacy-preserving framework for deploying domain-adapted LLM systems within pharmaceutical organisations. The framework integrates Retrieval-Augmented Generation (RAG) over a locally maintained semantic vector index, multimodal input handling for text, documents, and images, role-based access control (RBAC), a query governance layer, a red-teaming-informed safety testing methodology, and a human-in-the-loop (HITL) verification mechanism designed to build progressive organisational trust in AI-generated outputs. The architecture is explicitly designed as a flexible blueprint: specific components, including the choice of language model, embedding model, and vector store, are interchangeable depending on organisational infrastructure, data sensitivity requirements, and available computational resources. A prototype software tool has been developed to demonstrate the approach's feasibility.
Pharmaceutical manufacturing is among the most knowledge-intensive and regulatory-constrained industries in the global economy. Organisations operating in this sector maintain extensive internal document repositories, encompassing standard operating procedures (SOPs), batch manufacturing records, analytical methods, regulatory dossiers, quality management documentation, and proprietary formulation data. The efficient retrieval and synthesis of this institutional knowledge is critical not only to day-to-day operational efficiency but to the safety, quality, and regulatory compliance of manufactured drug substances and drug products.
The emergence of large language models (LLMs) has created significant new possibilities for intelligent document interaction, natural language querying, and automated knowledge synthesis. Models capable of understanding complex scientific and procedural text, answering nuanced domain-specific questions, and generating structured reports from unstructured documentation represent a potentially transformative capability for pharmaceutical organisations. However, deploying general-purpose LLMs in this context faces three fundamental, interrelated obstacles.
The first is the knowledge gap. State-of-the-art LLMs are trained on broad public corpora and have no inherent awareness of an organisation's internal processes, proprietary terminology, specific equipment configurations, or regulatory history. Responses generated without grounding in organisational documents are prone to hallucinating the production of plausible-sounding but factually incorrect output, which is particularly dangerous in contexts where decisions affect product quality or patient safety.
The second is the data sovereignty constraint. Regulatory frameworks governing pharmaceutical operations, including FDA 21 CFR Part 11, ICH Q10, GDPR, and HIPAA, impose strict requirements on where and how proprietary data may be processed and stored. Transmitting batch records, formulation data, or regulatory submissions to third-party cloud AI APIs may constitute a regulatory violation and expose organisations to significant intellectual property and compliance risk. This makes the naive adoption of cloud-hosted LLM services fundamentally incompatible with the operational and regulatory requirements of most pharmaceutical manufacturers.
The third is the system integrity and misuse risk. Even an internally deployed system, if inadequately controlled, may be exploited by authorised users to extract information beyond their access level, or manipulated through adversarial query techniques to produce outputs the system was designed to prevent. In pharmaceutical contexts, this risk extends to the potential exposure of trade secrets, regulatory strategies, or personnel-sensitive data.
This paper addresses all three obstacles by proposing a modular, privacy-preserving LLM framework specifically designed for pharmaceutical manufacturing environments. The framework combines Retrieval-Augmented Generation (RAG) with fully local or hybrid deployment options, role-based access control, a query governance layer, red-teaming-informed safety testing, and a human-in-the-loop verification layer. Critically, the framework is designed as an adaptable architectural blueprint rather than a fixed implementation — specific component choices are left to the implementing organisation based on their resources, infrastructure, and regulatory posture. A prototype implementation demonstrates the feasibility of the approach, though formal quantitative evaluation is identified as a primary direction for future work.
Background and Motivation
Knowledge Management Challenges in Pharmaceutical Manufacturing
Pharmaceutical manufacturing organisations, particularly those engaged in continuous API (active pharmaceutical ingredient) manufacturing, operate under conditions of exceptional document complexity. A single manufacturing campaign may involve cross-referencing dozens of SOPs, batch records, analytical specifications, equipment logbooks, and regulatory commitments. This documentation is typically distributed across disparate file systems, electronic document management systems (EDMS), and paper archives — creating significant barriers to efficient knowledge retrieval.
Traditional keyword-based search systems are inadequate for this environment because they fail to capture semantic intent. For example, a technician seeking guidance from AI (e.g., LLM) on particle size distribution in a milling operation may use terminology that differs from the precise language of the controlling SOP, leading to missed or irrelevant results. The cognitive load of manual document review in time-sensitive manufacturing situations represents both a productivity cost and a potential quality risk.
Regulatory Constraints on AI Adoption
The adoption of AI systems in pharmaceutical manufacturing is subject to a regulatory oversight framework that does not yet have comprehensive guidance specific to LLMs, but whose foundational principles apply directly. FDA 21 CFR Part 11 requires that electronic records used in regulated activities be accurate, reliable, and protected against unauthorised access or alteration. ICH Q10 establishes expectations for pharmaceutical quality systems that emphasise documented control, change management, and continual improvement principles that must be reflected in any AI system integrated into manufacturing workflows.
Beyond domestic regulations, pharmaceutical organisations operating in global markets must comply with EMA guidance, ICH Q9 quality risk management principles, and the data protection requirements of jurisdictions in which they operate. Any AI deployment framework for pharmaceutical use must be designed with auditability, access control, and data sovereignty as first-order design requirements, not afterthoughts.
Why General-Purpose Cloud LLMs Are Insufficient
The rapid advancement of publicly available LLM services has created significant interest in their potential pharmaceutical applications. However, several characteristics of these services limit their suitability for regulated pharmaceutical environments. First, they lack organisational knowledge: without access to internal documents, their responses to domain-specific queries are based on general training data that may not reflect an organisation's specific processes, equipment, or regulatory commitments. Second, they require data transmission to external infrastructure: submitting proprietary documents or queries containing sensitive information to cloud APIs (Application Programming Interfaces) creates regulatory exposure and intellectual property risk. Third, they offer limited auditability: cloud LLM services typically do not provide the detailed interaction logs, source attribution, and human oversight mechanisms required to integrate AI outputs into regulated workflows. Fourth, they provide no mechanism for access-level enforcement or query governance aligned with organisational policies.
An important clarification is warranted regarding the design philosophy of this framework. The solution proposed here does not require organisations to build or train their own LLM from scratch — a task that would be prohibitively expensive and technically impractical for most pharmaceutical manufacturers. Instead, the framework deploys publicly available open-weight models locally, within the organisation's own infrastructure. The organisation is not creating a model; it is running one, in the same way it runs any enterprise software. This distinction is critical to understanding the framework's feasibility and cost structure.
These limitations reflect a mismatch between the design assumptions of general-purpose consumer AI services and the specific operational and regulatory requirements of pharmaceutical manufacturing. The framework proposed in this paper is designed to resolve this mismatch.
Related Work
Domain Adaptation of Large Language Models
The adaptation of pre-trained LLMs to specific domains has been pursued through several complementary approaches. Fine-tuning involves updating model parameters on domain-specific datasets and has demonstrated effectiveness in biomedical text understanding, clinical note analysis, and legal document processing. However, fine-tuning is computationally expensive, requires curated labeled data, and necessitates retraining whenever organisational knowledge evolves characteristics that limit its practicality for dynamic document environments.
Prompt engineering approaches, including few-shot prompting and chain-of-thought reasoning, enable behavioral guidance without parameter updates but are constrained by context window limitations and the absence of persistent organisational memory. These limitations make prompt-only strategies insufficient for comprehensive knowledge management applications.
Retrieval-Augmented Generation
Retrieval-Augmented Generation (RAG) addresses the knowledge limitations of standalone LLMs by coupling generative models with external retrieval mechanisms. At inference time, semantically relevant documents are retrieved from a knowledge base and provided to the model as context, enabling responses grounded in current, organisation-specific information without retraining. Dense vector retrieval using embedding models enables semantic similarity search that goes beyond keyword matching, retrieving relevant content even when query terminology differs from document language.
RAG has emerged as the preferred architecture for enterprise knowledge management applications due to its modularity, interpretability, and significantly lower maintenance overhead compared to fine-tuning. The source documents underlying any response can be identified and inspected, providing a level of response traceability not available from parametric knowledge alone, a property of particular value in regulated environments.
Human-in-the-Loop AI Systems
Human-in-the-loop (HITL) systems incorporate structured human judgment into automated decision pipelines to improve reliability and maintain accountability. In high-stakes domains such as healthcare, financial services, and safety-critical manufacturing, HITL mechanisms provide the oversight layer necessary to detect and correct AI errors before they propagate into operational decisions. In the context of LLM deployment, HITL frameworks allow domain experts to validate model outputs, annotate failures, and provide corrective feedback that can be used for systematic system improvement.
Privacy-Preserving and On-Premise AI Deployment
The availability of open-weight language models has enabled on-premise LLM deployment without dependence on cloud APIs. Orchestration frameworks facilitate the construction of RAG pipelines over locally hosted models, while quantisation techniques have made it feasible to run capable language models on commodity hardware. These developments create the technical foundation for the fully local or hybrid deployment architecture proposed in this framework.
AI Security and Adversarial Robustness
The deployment of LLMs in sensitive organisational contexts introduces security considerations that extend beyond data privacy. Prompt injection attacks in which adversarially constructed user inputs attempt to override system-level instructions or extract information the system was configured to withhold represent a well-documented vulnerability class in deployed LLM systems. Red teaming, originally a concept from military and security testing, has been adapted as a structured methodology for identifying failure modes and safety vulnerabilities in AI systems before deployment. Incorporating adversarial testing into the deployment lifecycle of organisational AI systems is increasingly recognised as a best practice for responsible AI governance.
Proposed Framework
The proposed framework is a modular, end-to-end architecture for deploying organisation-adapted LLM systems in pharmaceutical manufacturing environments. It is designed around five core design principles:
• Privacy by default: organisational documents and query data are processed locally; no proprietary content is transmitted to external services unless explicitly configured and approved.
• Modularity: each component of the pipeline, the language model, embedding model, vector store, and verification interface, is independently replaceable based on organisational requirements and available infrastructure.
• Traceability: every response is linked to the source documents from which it was derived, supporting regulatory auditability and user verification.
• Progressive trust: the human verification layer is designed as a transitional mechanism that builds documented evidence of system reliability, enabling organisations to calibrate their reliance on AI outputs proportionally to demonstrated accuracy.
• Security by design: access control, query governance, and adversarial testing are integrated into the architecture from the ground up rather than added as post-deployment patches.
The framework consists of seven functional layers: the document ingestion layer, the retrieval layer, the generation layer, the access control layer, the query governance layer, the verification and feedback layer, and the administrative oversight layer. Each is described in the sections that follow.
Conclusions
This article has presented a modular, privacy-preserving framework for deploying domain-adapted large language model systems in pharmaceutical manufacturing organisations. The framework addresses the three principal obstacles to LLM adoption in this context: the knowledge gap between general-purpose models and organization-specific content, resolved through retrieval-augmented generation over a locally maintained document index; the data sovereignty constraint imposed by pharmaceutical regulatory frameworks, resolved through local or hybrid deployment architectures; and the system integrity risk associated with insider threats and adversarial exploitation, addressed through role-based access control, query governance, and red-teaming-informed safety testing.
Acknowledgements
This work is supported by the US Food and Drug Administration (FDA) under contract number 75F40125C00089
References
1. Howard, J., & Ruder, S. (2018). Universal Language Model Fine-tuning for Text Classification. Proceedings of ACL, 328–339.
2. Lee, J., et al. (2020). BioBERT: A Pre-trained Biomedical Language Representation Model for Biomedical Text Mining. Bioinformatics, 36(4), 1234–1240.
3. Chalkidis, I., et al. (2020). LEGAL-BERT: The Muppets Straight out of Law School. Findings of EMNLP, 2898–2904.
4. Wei, J., et al. (2022). Chain-of-Thought Prompting Elicits Reasoning in Large Language Models. Advances in NeurIPS, 35, 24824–24837.
5. Lewis, P., et al. (2020). Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks. Advances in NeurIPS, 33, 9459–9474.
6. Settles, B. (2009). Active Learning Literature Survey. University of Wisconsin-Madison, CS Technical Report.
7. Monarch, R. M. (2021). Human-in-the-Loop Machine Learning. Manning Publications.
8. Amodei, D., et al. (2016). Concrete Problems in AI Safety. arXiv:1606.06565.
9. Touvron, H., et al. (2023). LLaMA 2: Open Foundation and Fine-Tuned Chat Models. arXiv:2307.09288.
10. Jiang, A. Q., et al. (2023). Mistral 7B. arXiv:2310.06825.
11. Perez, F., & Ribeiro, I. (2022). Ignore Previous Prompt: Attack Techniques for Language Models. NeurIPS ML Safety Workshop.
12. Ganguli, D., et al. (2022). Red Teaming Language Models to Reduce Harms: Methods, Scaling Behaviors, and Lessons Learned. arXiv:2209.07858.
13. Zhang, T., et al. (2020). BERTScore: Evaluating Text Generation with BERT. ICLR 2020.
